JP2009525758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525758A5 JP2009525758A5 JP2008554427A JP2008554427A JP2009525758A5 JP 2009525758 A5 JP2009525758 A5 JP 2009525758A5 JP 2008554427 A JP2008554427 A JP 2008554427A JP 2008554427 A JP2008554427 A JP 2008554427A JP 2009525758 A5 JP2009525758 A5 JP 2009525758A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- par
- binding protein
- antigen binding
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004913 activation Effects 0.000 claims description 3
- 102000032628 PAR-2 Receptor Human genes 0.000 claims 9
- 108010070503 PAR-2 Receptor Proteins 0.000 claims 9
- 102000025171 antigen binding proteins Human genes 0.000 claims 8
- 108091000831 antigen binding proteins Proteins 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 241000288906 Primates Species 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 241000700199 Cavia porcellus Species 0.000 claims 1
- 241000699800 Cricetinae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000282577 Pan troglodytes Species 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000005095 gastrointestinal system Anatomy 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 description 10
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 10
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77245606P | 2006-02-10 | 2006-02-10 | |
| US60/772,456 | 2006-02-10 | ||
| PCT/US2007/003796 WO2007092640A2 (en) | 2006-02-10 | 2007-02-09 | Antibodies that bind par-2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009525758A JP2009525758A (ja) | 2009-07-16 |
| JP2009525758A5 true JP2009525758A5 (cg-RX-API-DMAC10.html) | 2010-04-02 |
| JP5255453B2 JP5255453B2 (ja) | 2013-08-07 |
Family
ID=38345850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008554427A Active JP5255453B2 (ja) | 2006-02-10 | 2007-02-09 | Ｐａｒ−２に結合する抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7888482B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1981913B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5255453B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2007212195B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2638849C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2476892T3 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2008009886A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2007092640A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008001887A1 (es) * | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| WO2009020748A2 (en) * | 2007-07-16 | 2009-02-12 | Avaxia Biologics, Inc. | Antibody therapy for modulating function of intestinal receptors |
| WO2009046168A1 (en) | 2007-10-02 | 2009-04-09 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
| WO2010017086A1 (en) * | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Effectors of par-2 activation and their use in the modulation of inflammation |
| WO2010132954A1 (en) * | 2009-05-21 | 2010-11-25 | Oral Health Australia Pty Ltd | Method of treating periodontal disease by administering antagonists of par-2 |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| MY162557A (en) | 2010-02-26 | 2017-06-15 | Oral Health Australia Pty Ltd | Treatment or prevention of infection |
| WO2012077105A2 (en) * | 2010-12-07 | 2012-06-14 | Bio-Marcare Technologies Ltd. | Biomarkers for detecting a cancerous state in a subject |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| EP3712166A1 (en) | 2013-09-05 | 2020-09-23 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| HK1223096A1 (zh) | 2013-09-25 | 2017-07-21 | Vertex Pharmaceuticals Incorporated | 用作par-2信號通路抑制劑的咪唑並噠嗪 |
| WO2015175861A1 (en) | 2014-05-16 | 2015-11-19 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| AU2018235928B2 (en) | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| KR20220098056A (ko) * | 2018-02-09 | 2022-07-08 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
| US12325737B2 (en) | 2018-03-26 | 2025-06-10 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| AU2020250933A1 (en) | 2019-04-05 | 2021-10-28 | Centre Hospitalier Régional Et Universitaire De Brest | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| KR20220069982A (ko) | 2019-09-26 | 2022-05-27 | 암젠 인크 | 항체 조성물의 생산 방법 |
| EP4045515A4 (en) | 2019-10-18 | 2023-10-18 | The Regents Of The University Of Michigan | BIOMATERIAL SENSOR SYSTEMS |
| WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| AU2021328375A1 (en) * | 2020-08-18 | 2023-04-13 | Cephalon Llc | Anti-PAR-2 antibodies and methods of use thereof |
| CN112229996A (zh) * | 2020-08-25 | 2021-01-15 | 深圳市第二人民医院(深圳市转化医学研究院) | 蛋白酶激活受体2作为宫颈癌转移检测标志物的应用 |
| US20240043501A1 (en) | 2020-10-15 | 2024-02-08 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| JP2024537100A (ja) | 2021-10-05 | 2024-10-10 | アムジエン・インコーポレーテツド | Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量 |
| GB202204159D0 (en) * | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| JP2026516670A (ja) | 2023-04-20 | 2026-05-26 | アムジエン・インコーポレーテツド | 相対的な不対グリカン含有量を決定する方法 |
| AU2024325342A1 (en) | 2023-08-14 | 2026-02-26 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2026090253A1 (en) | 2024-10-23 | 2026-04-30 | Amgen Inc. | Methods of determining glycan pairing content |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629174A (en) | 1993-07-26 | 1997-05-13 | Cor Therapeutics, Inc. | Recombinant C140 receptor |
| US6297026B1 (en) | 1993-07-26 | 2001-10-02 | Cor Therapeutics Inc. | Nucleic acids encoding the C140 receptor |
| AU5895500A (en) * | 1999-06-29 | 2001-01-31 | Cor Therapeutics, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| AU2001231030A1 (en) | 2000-01-20 | 2001-07-31 | Amgen Inc | Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics |
| US20070053911A1 (en) | 2003-03-11 | 2007-03-08 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) |
| AR070911A1 (es) | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| WO2010017086A1 (en) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Effectors of par-2 activation and their use in the modulation of inflammation |
-
2007
- 2007-02-08 US US11/704,529 patent/US7888482B2/en active Active
- 2007-02-09 WO PCT/US2007/003796 patent/WO2007092640A2/en not_active Ceased
- 2007-02-09 AU AU2007212195A patent/AU2007212195B2/en active Active
- 2007-02-09 MX MX2008009886A patent/MX2008009886A/es active IP Right Grant
- 2007-02-09 ES ES07763386.5T patent/ES2476892T3/es active Active
- 2007-02-09 EP EP07763386.5A patent/EP1981913B1/en active Active
- 2007-02-09 JP JP2008554427A patent/JP5255453B2/ja active Active
- 2007-02-09 CA CA2638849A patent/CA2638849C/en active Active
-
2011
- 2011-01-18 US US13/008,736 patent/US8287872B2/en active Active
-
2012
- 2012-09-27 US US13/629,373 patent/US20130189281A1/en not_active Abandoned